# Artiva Biotherapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Artiva Biotherapeutics, Inc.). ## Overview Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancer. Its lead program, AlloNK (AB-101), is a cryopreserved, off-the-shelf NK cell therapy designed to work with monoclonal antibodies to enhance B-cell depletion through ADCC. The company is currently focused on refractory rheumatoid arthritis as its lead autoimmune indication, while also evaluating AlloNK in other B-cell driven autoimmune diseases such as Sjögren’s disease. Artiva has built a cGMP manufacturing center in San Diego to support clinical supply, process optimization, and future commercial production if its programs are approved. ## Products & services • AlloNK (AB-101) allogeneic NK cell therapy • Clinical development for refractory rheumatoid arthritis • Clinical development for Sjögren’s disease and other autoimmune diseases • Combination therapy support with monoclonal antibodies • cGMP manufacturing and cryopreservation of cell therapy product - **Lead cell therapy candidate** (85%) — AlloNK (AB-101), an allogeneic, non-genetically modified NK cell therapy intended to enhance antibody-driven B-cell depletion. - **Clinical development programs** (10%) — Ongoing trials and regulatory work for autoimmune disease indications, especially refractory rheumatoid arthritis and Sjögren’s disease. - **Manufacturing and supply** (5%) — Internal and partner-supported manufacturing, cryopreservation, fill-finish, and clinical supply logistics for cell therapy products. - AlloNK (AB-101) allogeneic NK cell therapy - Clinical development for refractory rheumatoid arthritis - Clinical development for Sjögren’s disease and other autoimmune diseases - Combination therapy support with monoclonal antibodies - cGMP manufacturing and cryopreservation of cell therapy product ## Customers Artiva does not yet sell approved products commercially, so its current 'customers' are primarily clinical trial sites, collaborators, and future pharmaceutical partners rather than end patients. In the near term, the company’s programs are bought into by investigators, trial sponsors, and partner companies that need AlloNK supply for combination studies and clinical development. If approved, the commercial customer base would shift to physicians, hospitals, and specialty treatment centers serving patients with refractory autoimmune disease or certain cancers. The company also depends on contract manufacturing and logistics partners that support production, storage, and distribution of frozen cell therapy product. - **Clinical trial sponsors and investigators** (primary) — They use AlloNK in ongoing studies to generate efficacy, safety, and dose-response data needed for regulatory advancement. - **Future autoimmune disease treatment centers** (secondary) — Hospitals and specialty clinics would administer AlloNK if approved for refractory rheumatoid arthritis or related autoimmune indications. - **Biopharma collaboration partners** (primary) — Partners may combine AlloNK with monoclonal antibodies or other agents to broaden development and commercialization reach. - **Patients with refractory autoimmune disease** (primary) — Patients are the ultimate end users, especially those with B-cell driven diseases that have not responded to standard therapies. - Clinical investigators and trial sites running AlloNK studies - Patients enrolled in autoimmune disease and oncology trials - Pharmaceutical partners using AlloNK in combination regimens - Hospitals and specialty centers as future treatment sites - Contract manufacturing and logistics partners supporting supply chain ## Geography Artiva is headquartered in the United States and operates its manufacturing center in San Diego, California. The company’s current business is concentrated in U.S.-based research, clinical development, and manufacturing activities, with no disclosed country-level revenue breakdown in the provided filings. Its collaboration history includes U.S. and certain other countries under the Affimed agreement, although that collaboration was terminated in 2025 after Affimed entered insolvency. Geography matters mainly because clinical trials, regulatory interactions, and manufacturing quality systems are all anchored in the U.S., while future commercialization could require broader international supply and regulatory execution. - Headquartered in the United States - San Diego manufacturing center supports clinical and future commercial supply - U.S. clinical development is the core operating footprint - No country-level revenue disclosure was provided in the excerpts - Prior collaboration covered the U.S. and certain other countries ## Strategy Artiva’s near-term strategy is to advance AlloNK in refractory rheumatoid arthritis and use early clinical data to support a pivotal trial design discussion with the FDA in 2026. The company is also broadening its autoimmune basket trial work, which helps it test whether the same NK-cell mechanism can work across multiple B-cell driven diseases. Manufacturing is a strategic priority because the company has invested in its San Diego facility to improve process control, support clinical trials, and prepare for potential commercial launch. Following the termination of the Affimed collaboration, Artiva is likely to rely more heavily on internal execution and selective partnerships to extend its pipeline and commercial options. - **Generate clinical proof-of-concept in refractory rheumatoid arthritis** (short-term) — RA is the lead indication and the clearest path to a registrational strategy for AlloNK. - **Broaden autoimmune disease applicability** (medium-term) — A multi-indication profile could improve the commercial opportunity and reduce dependence on one disease. - **Build manufacturing and supply readiness** (medium-term) — Cell therapy commercialization depends on reliable, scalable, cGMP-compliant production and cold-chain logistics. - Advance AlloNK in refractory rheumatoid arthritis - Use 2026 clinical data to support pivotal trial planning with FDA - Expand evidence across B-cell driven autoimmune diseases - Leverage the San Diego facility for process optimization and supply - Maintain optionality for future commercial launch and partnerships ## Risks Artiva faces the classic risks of a clinical-stage biotech company: no approved products, no product sales, and a need to fund expensive development for an uncertain period. Its lead program depends on successful clinical results, regulatory alignment, and the ability to manufacture cell therapy product without contamination or supply interruptions. Competition is intense across allogeneic NK, CAR-NK, CAR-T, and bispecific antibody platforms, so weak efficacy or safety data could quickly reduce partnering and commercialization prospects. The company also faces execution risk from its reliance on specialized manufacturing, cold-chain logistics, and third-party collaborators, as shown by the termination of the Affimed collaboration after Affimed’s insolvency. - **Clinical development failure for AlloNK** [critical] — The company’s value depends heavily on positive safety and efficacy data in refractory RA and other autoimmune indications. - **Manufacturing contamination or supply disruption** [high] — Cell therapy production is sensitive to microbial or viral contamination and biologic raw material shortages, which can halt trials. - **Capital dilution and funding shortfall** [high] — The company expects continued operating losses and will need additional financing before any product revenue is possible. - **Competitive displacement** [high] — Many biotech and pharma companies are pursuing allogeneic NK, CAR-T, CAR-NK, and bispecific approaches in overlapping indications. - **Collaboration and counterparty risk** [medium] — The terminated Affimed collaboration shows that partner distress can remove a development path and reduce external support. - No approved products or product sales yet - Clinical trial failure could eliminate or delay the lead program - Cell therapy manufacturing contamination or raw material shortages - Intense competition from larger biotech and pharma companies - Dependence on regulatory feedback for pivotal trial design - Partner insolvency or collaboration termination can disrupt development - Need for substantial additional capital before commercialization ## Accounting Artiva is a pre-commercial biotech, so reported results are dominated by research and development expense, general and administrative overhead, and occasional collaboration-related revenue rather than product sales. Revenue recognition is limited and appears tied to development support activities under the AB-201 agreement, making timing and contract scope important for quarter-to-quarter comparability. The company capitalizes payments made before receipt of R&D goods or services and then recognizes expense as the services are received, which can affect the timing of reported R&D costs and accrued liabilities. Because it is still building its own manufacturing capability, judgments around facility costs, outsourced development, and clinical supply commitments are important to understanding cash burn and future expense growth. - **Revenue recognition on development support** — Affects reported revenue and comparability across quarters - **Accrued research and development costs** — Affects operating expenses and current liabilities - **Capitalization of prepayments for R&D services** — Affects timing of expense recognition and cash flow interpretation - **Facility and manufacturing cost allocation** — Affects operating expense trajectory and future margin profile - Revenue is limited to collaboration or development support activities - R&D expense timing depends on when outsourced services are received - Prepayments for R&D services are capitalized until goods or services arrive - Accrued R&D costs can materially affect period-end liabilities - Facility and manufacturing build-out costs influence future expense run-rate - Quarterly results can be volatile because revenue is small and non-recurring --- *Last updated: 2026-08-11T04:46:21.461540+00:00*